article thumbnail

AstraZeneca hit CEO Pascal Soriot's $45B revenue goal after all. But is Enhertu approaching a plateau?

Fierce Pharma

billion in 2023 revenues, AstraZeneca has met the $45 billion-by-2023 goal CEO Pascal Soriot established in 2014 when he was fending off a takeover bid from Pfizer. AstraZeneca has met the $45 billion-by-2023 revenue goal that CEO Pascal Soriot established in 2014.

321
321
article thumbnail

Takeda picks up 2nd FDA-approved indication for immune globulin treatment HyQvia

Fierce Pharma

It is the second indication for HyQvia, which was first endorsed in 2014. The FDA has approved Takeda's HyQvia as a maintenance therapy for CIDP.

FDA 290
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

J&J's tuberculosis med Sirturo lands full US, EU approvals after more than a decade on the market

Fierce Pharma

The traditional approvals follow initial accelerated approvals granted by the FDA in 2012 and the European Commission in 2014. It took many years, but Johnson & Johnson’s tuberculosis med Sirturo can finally claim full approvals in the U.S. and Europe following initial conditional nods. |

Marketing 296
article thumbnail

Takeda ponies up €130M to settle tax linked to distant AbbVie-Shire breakup fee

Fierce Pharma

Back in 2018, Irish authorities hit Shire with a €398 million charge tied to that company’s rejection of AbbVie’s takeover bid in 2014. . | Takeda will pay €130 million (about $137 million) to resolve a tax assessment from the Irish Revenue Commissioners, the company said Wednesday. Takeda ultimately purchased Shire for $62 billion in 2019.

278
278
article thumbnail

AstraZeneca uses Farxiga's versatility to guide pipeline work, exec says

Fierce Pharma

With seven posters and nine presentations on Farxiga over the weekend at the European Society of Cardiology (ESC) scientific sessions in Amsterdam, AstraZeneca made it clear that it has lots to say | As AstraZeneca's Farxiga has added four indications over the last five years—on top of its initial 2014 approval for Type 2 diabetes—its spillover (..)

246
246
article thumbnail

Report: Percentage of Workers Eligible for Employment-Based Coverage Increased 5% Since 2014

MedCity News

It was expected that the Affordable Care Act would lead to many employers dropping health benefits, but that did not happen, a new report from the Employee Benefit Research Institute found.

Leads 119
article thumbnail

How EU 536/2014 Will Revolutionize Global Clinical Trials

PharmExec

November 3rd 2022 9 am CT |10 am ET | 2 pm GMT | 3pm CET The way clinical trials are conducted in the European Union is undergoing major changes with (EU) No 536/2014.

52